Losartan Potassium — $0 on Listed Strengths

About Losartan Potassium

Losartan potassium is a widely prescribed medication vital for managing high blood pressure and protecting heart health. For many, the cost of essential prescriptions can be a burden.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Losartan Potassium is approved for (FDA label)

Losartan potassium tablets, USP are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Losartan Potassium (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan potassium tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [ see Warnings and Precautions ( 5.1 )]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue losartan potassium tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: a397502e-abe7-49cf-97c7-d53a616947eb. SPL document ID: 5a9625fa-0c62-f50f-e063-6394a90a5b82. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Losartan Potassium (FDA label)

• Losartan potassium tablets, USP 100 mg are white to off white oval, biconvex film-coated tablets with CL17 on one side and plain on the other. Tablets: 100 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: a397502e-abe7-49cf-97c7-d53a616947eb. SPL document ID: 5a9625fa-0c62-f50f-e063-6394a90a5b82. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Losartan Potassium (FDA label)

Most common adverse reactions (incidence ≥2% and greater than placebo) are: dizziness, upper respiratory infection, nasal congestion, and back pain. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc. at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypertension Losartan potassium tablets has been evaluated for safety in more than 3300 adult patients treated for essential hypertension and 4058 patients/subjects overall.

Source: FDA prescribing information (DailyMed). Set ID: a397502e-abe7-49cf-97c7-d53a616947eb. SPL document ID: 5a9625fa-0c62-f50f-e063-6394a90a5b82. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Losartan Potassium (FDA label)

Losartan potassium tablets are contraindicated: • In patients who are hypersensitive to any component of this product. • For coadministration with aliskiren in patients with diabetes. • Hypersensitivity to any component. ( 4 ) • Coadministration with aliskiren in patients with diabetes. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: a397502e-abe7-49cf-97c7-d53a616947eb. SPL document ID: 5a9625fa-0c62-f50f-e063-6394a90a5b82. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Losartan Potassium (FDA label)

• Hypotension: Correct volume or salt depletion prior to administration of losartan potassium tablets. ( 5.2 ) • Monitor renal function and potassium in susceptible patients. ( 5.3 , 5.4 ) 5.1 Fetal Toxicity Losartan potassium can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

Source: FDA prescribing information (DailyMed). Set ID: a397502e-abe7-49cf-97c7-d53a616947eb. SPL document ID: 5a9625fa-0c62-f50f-e063-6394a90a5b82. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Losartan Potassium (FDA label)

• Agents Increasing Serum Potassium: Risk of hyperkalemia. ( 7.1 ) • Lithium: Risk of lithium toxicity. ( 7.2 ) • NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7.3 ) • Dual Inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7.4 ) 7.1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists.

Source: FDA prescribing information (DailyMed). Set ID: a397502e-abe7-49cf-97c7-d53a616947eb. SPL document ID: 5a9625fa-0c62-f50f-e063-6394a90a5b82. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.